Semaglutide CAS 910463-68-2
CAS Number: 910463-68-2
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight: ~4113.6 g/mol
Name: Semaglutide
CAS Number: 910463-68-2
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight: ~4113.6 g/mol
Structure: Long-chain GLP-1 receptor agonist peptide (modified analogue of human GLP-1).
How Semaglutide Works for Fat Loss
Semaglutide works by binding to GLP-1 receptors, triggering satiety signals in the brain while slowing gastric emptying. This dual action leads to:
● Decreased appetite and cravings
● Enhanced feeling of fullness
● Lower daily caloric intake
● Progressive fat loss and improved body composition
Clinical studies show users experience consistent body-weight reduction even without extreme dieting, making Semaglutide for fat loss a preferred choice among individuals aiming for sustainable results.
Semaglutide Peptide for Men
While Semaglutide benefits both genders, men often experience distinct metabolic advantages due to higher lean-muscle mass and testosterone-linked energy balance. For men, Semaglutide can:
● Improve fat-to-muscle ratio
● Help manage appetite while maintaining strength
● Support long-term weight control when paired with active training and proper nutrition
In fitness communities, Semaglutide peptide for man has become a trending solution for reshaping body composition without severe caloric restriction.
Semaglutide Clinical Trial Data Summary
STEP Program (Weight Loss / Obesity Trials)
|
Trial |
Population |
Formulation |
Duration |
Average Weight Loss |
Key Notes |
|
STEP 1 |
Adults with obesity (no diabetes) |
Weekly injection |
68 weeks |
~15% body weight |
Most participants lost ≥10%; lifestyle changes included. |
|
STEP 2 |
Adults with type 2 diabetes + obesity |
Weekly injection |
68 weeks |
~9.6% body weight |
Effective even in patients with diabetes; slightly less than STEP 1. |
|
STEP 3 |
Adults with obesity |
Weekly injection + behavioral therapy |
68 weeks |
~16% body weight |
Adding behavioral therapy increased adherence and results. |
|
STEP 4 |
Adults with obesity |
Weekly injection (continuation vs withdrawal) |
68 weeks |
Continuation: ~17% maintained; Withdrawal: regained ~6% |
Stopping semaglutide led to weight regain. |
SUSTAIN Program (Type 2 Diabetes Trials)
|
Trial |
Population |
Formulation |
Duration |
HbA1c Reduction |
Weight Loss |
Key Notes |
|
SUSTAIN 1 |
Type 2 diabetes, drug-naive |
Weekly injection |
30 weeks |
↓ 1.5–1.8% |
~3–4 kg |
Strong glucose and weight impact vs placebo. |
|
SUSTAIN 2 |
Type 2 diabetes on oral meds |
Weekly injection |
56 weeks |
↓ 1.3–1.6% |
~4–6 kg |
Superior to sitagliptin (DPP-4 inhibitor). |
|
SUSTAIN 6 |
Type 2 diabetes, high CV risk |
Weekly injection |
104 weeks |
↓ 1.1–1.5% |
~4–5 kg |
Reduced cardiovascular events (non-fatal stroke, MI). |
|
SUSTAIN 7 |
Type 2 diabetes |
Weekly injection |
40 weeks |
↓ 1.5–1.8% |
~5–6 kg |
Better than dulaglutide in glucose and weight outcomes. |
Key Insights
- Weight Loss Effect: Semaglutide 2.4 mg weekly led to ~15% body weight reduction in non-diabetic obese adults (STEP 1).
- Diabetes Effect: Reduced HbA1c by 1.0–1.8% and supported 4–6 kg weight loss in type 2 diabetes patients.
- Oral vs Injectable: Oral semaglutide effective but slightly less potent for weight loss than injectable.
- Cardiovascular Safety: Reduced risk of major adverse cardiovascular events in high-risk patients.
- Withdrawal Effect: Discontinuation often leads to weight regain, indicating need for long-term use.
Usage Recommendations
- Form & Preparation: Supplied as lyophilized Semaglutide Powder for weight loss studies. Reconstitute according to laboratory protocols using sterile water or appropriate solvent.
- Suggested Research Cycles: Short-Term (8–12 weeks) for initial evaluations; Extended (16–24 weeks) for long-term obesity research; Maintenance studies to examine sustained fat loss.
- Administration in Research: Studied both as Semaglutide Tablets (oral daily) and injectable forms (weekly). Both routes compared for absorption and effectiveness.
- Combination Studies: Paired with calorie restriction, high-protein diets, resistance + cardio exercise, or compared with other metabolic peptides.
- Monitoring Parameters: Weight, BMI, body fat %, blood glucose, insulin sensitivity, HbA1c, and gastrointestinal tolerance.
- Storage & Stability: Store powder at -20°C long-term. Protect from light and moisture. Reconstituted solutions typically refrigerated for short-term use.
⚠️ Important: Research use only. Not for human consumption, diagnosis, or therapeutic purposes.
Quality Assurance
Worldwide Shipping
Message us to get your personalized quotation within 24 hours.
-
Whatsapp:+852 6736 4057
-
Telegram:@hinovopept
-
Email:novopept@gmail.com
Hot Tags: semaglutide cas 910463-68-2, China semaglutide cas 910463-68-2 manufacturers, suppliers, levothyroxine sodium 25 mcg, Orlistat lipase inhibitor, Semaglutide for fat loss, Survodutide CAS 2805997 46 8, tirzepatide fat loss, tirzepatide weight loss
Send Inquiry
